GREENWICH LIFESCIENCES, INC. Stock Repurchased During Period, Shares
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- GREENWICH LIFESCIENCES, INC. stock repurchased during period, shares for the quarter ending 2023-09-30 was 0.00 shares.
- GREENWICH LIFESCIENCES, INC. stock repurchased during period, shares for the quarter ending 2023-06-30 was 0.00 shares.
- GREENWICH LIFESCIENCES, INC. stock repurchased during period, shares for the quarter ending 2023-03-31 was 0.00 shares.
| Period end | Stock Repurchased During Period, Shares 3 month | Stock Repurchased During Period, Shares 12 month |
|---|---|---|
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-19 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2025-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |